[go: up one dir, main page]

MX2015000778A - Metodo para purificar el factor transgenico vii. - Google Patents

Metodo para purificar el factor transgenico vii.

Info

Publication number
MX2015000778A
MX2015000778A MX2015000778A MX2015000778A MX2015000778A MX 2015000778 A MX2015000778 A MX 2015000778A MX 2015000778 A MX2015000778 A MX 2015000778A MX 2015000778 A MX2015000778 A MX 2015000778A MX 2015000778 A MX2015000778 A MX 2015000778A
Authority
MX
Mexico
Prior art keywords
factor vii
affinity ligand
transgenic factor
purifying
fvii
Prior art date
Application number
MX2015000778A
Other languages
English (en)
Other versions
MX358139B (es
Inventor
Damien Bataille
Michel Nogre
Sami Chtourou Abdessatar
Original Assignee
Français Du Fractionnement Et Des Biotechnologies Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Français Du Fractionnement Et Des Biotechnologies Lab filed Critical Français Du Fractionnement Et Des Biotechnologies Lab
Publication of MX2015000778A publication Critical patent/MX2015000778A/es
Publication of MX358139B publication Critical patent/MX358139B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un ligando de afinidad anti-Factor VII que es particularmente útil para purificar el factor VII activado humano recombinante de fuentes transgénicas. El ligando de afinidad combinado con otras etapas cromatográficas ortogonales permite la preparación de una solución de FVII muy purificada libre de agregados con un bajo porcentaje de formas de FVII degradadas u oxidadas.
MX2015000778A 2012-07-19 2013-07-18 Metodo para purificar el factor transgenico vii. MX358139B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305882.8A EP2687595B1 (en) 2012-07-19 2012-07-19 Method for purifying transgenic factor VII
PCT/EP2013/065205 WO2014013024A1 (en) 2012-07-19 2013-07-18 Method for purifying transgenic factor vii

Publications (2)

Publication Number Publication Date
MX2015000778A true MX2015000778A (es) 2015-10-14
MX358139B MX358139B (es) 2018-08-06

Family

ID=48856605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000778A MX358139B (es) 2012-07-19 2013-07-18 Metodo para purificar el factor transgenico vii.

Country Status (19)

Country Link
US (1) US9982247B2 (es)
EP (2) EP2687595B1 (es)
JP (1) JP6219947B2 (es)
KR (2) KR20140129015A (es)
CN (1) CN104640980B (es)
AR (1) AR091836A1 (es)
AU (1) AU2013291969B2 (es)
CA (1) CA2879109C (es)
DK (1) DK2875129T3 (es)
ES (1) ES2703541T3 (es)
IL (1) IL236755B (es)
MX (1) MX358139B (es)
MY (1) MY172995A (es)
PH (1) PH12015500083A1 (es)
PL (1) PL2875129T4 (es)
SG (1) SG11201500254PA (es)
TR (1) TR201818506T4 (es)
TW (1) TWI531576B (es)
WO (1) WO2014013024A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
US11553712B2 (en) 2010-12-30 2023-01-17 Laboratoire Français Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
FR3006591B1 (fr) * 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
FR3082427B1 (fr) * 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
CN114438061B (zh) * 2020-10-30 2023-10-20 北京双鹭立生医药科技有限公司 用于纯化凝血因子vii的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
FR2632524B1 (fr) 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
FR2677652B1 (fr) 1991-06-12 2005-05-27 Agronomique Inst Nat Rech Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee.
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
EP1589107B1 (en) 1992-08-21 2009-12-23 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
ATE204325T1 (de) * 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
TWI268933B (en) 2003-06-10 2006-12-21 Animal Technology Inst Taiwan Method for separating protein from animal milk
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
EP2271206A1 (fr) 2008-03-25 2011-01-12 Bioprotein Technologies Sa Lapins transgeniques producteurs de facteur vii humain
EP2285412A1 (en) 2008-05-23 2011-02-23 Novo Nordisk Health Care AG Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
CN102161701A (zh) * 2011-01-28 2011-08-24 上海兴迪金生物技术有限公司 从细胞培养液或血浆组分中分离纯化高纯度活化凝血七因子的方法

Also Published As

Publication number Publication date
JP2015522600A (ja) 2015-08-06
TW201416373A (zh) 2014-05-01
AR091836A1 (es) 2015-03-04
AU2013291969B2 (en) 2018-07-12
WO2014013024A1 (en) 2014-01-23
PH12015500083A1 (en) 2015-03-02
EP2687595A1 (en) 2014-01-22
EP2875129B1 (en) 2018-09-05
US9982247B2 (en) 2018-05-29
JP6219947B2 (ja) 2017-10-25
DK2875129T3 (en) 2019-01-07
TR201818506T4 (tr) 2019-01-21
MY172995A (en) 2019-12-18
IL236755B (en) 2018-03-29
CA2879109C (en) 2019-03-05
EP2687595B1 (en) 2018-05-30
KR20170083166A (ko) 2017-07-17
KR20140129015A (ko) 2014-11-06
US20150175983A1 (en) 2015-06-25
CN104640980B (zh) 2019-01-08
PL2875129T3 (pl) 2019-03-29
MX358139B (es) 2018-08-06
CA2879109A1 (en) 2014-01-23
SG11201500254PA (en) 2015-02-27
PL2875129T4 (pl) 2019-03-29
AU2013291969A1 (en) 2015-02-05
CN104640980A (zh) 2015-05-20
ES2703541T3 (es) 2019-03-11
TWI531576B (zh) 2016-05-01
EP2875129A1 (en) 2015-05-27
KR101842412B1 (ko) 2018-03-26

Similar Documents

Publication Publication Date Title
PH12015500083A1 (en) Method for purifying transgenic factor vii
PH12013501096B1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
IN2014DN00286A (es)
IN2014MN00093A (es)
MX2018010572A (es) Inmunoglobulinas heterodimericas.
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
EP4375371A3 (en) Methods for the manufacture of proteolytically processed polypeptides
WO2013022985A3 (en) Small molecule compounds for the control of nematodes
GT201500054A (es) Moléculas de enlace a il-18
IN2014DN08481A (es)
IN2014MN01378A (es)
SG10201805806RA (en) Modulation of Structured Polypeptide Specificity
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
IN2014CN03072A (es)
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
PL2831261T3 (pl) Sposób wytwarzania rekombinowanych białek o niskim poziomie DHNA (1,4-dihydroksy-2-naftoesanu)
IL233999A0 (en) Ligands for binding antibodies and protein conjugates containing antibodies and their use in chromatography
IN2014DN08412A (es)
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MX347541B (es) Analogos de acido sialico.
MX362393B (es) Cassette de expresion.
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
AR089245A1 (es) Procedimiento de purificacion de factor viii
EA201590778A1 (ru) ОЧИСТКА КОМБИНИРОВАННОЙ ГАЛАКТОЦЕРЕБРОЗИД-β-ГАЛАКТОЗИДАЗЫ ЧЕЛОВЕКА (rhGALC)
HK1198627A1 (zh) 纯丝状噬菌体及其制备方法

Legal Events

Date Code Title Description
FG Grant or registration